Antikoagulationsbehandling til særlige patientpopulationer

Gro Egholm; Jens Steen Olesen; Eva Birgitte Leinøe; Erik Lerkevang Grove; Jøn Dalsgaard Nielsen; Maja Hellfritzsch Poulsen

doi:10.61409/V05240367

Antikoagulationsbehandling til særlige patientpopulationer

Gro Egholm
, Jens Steen Olesen
, Eva Birgitte Leinøe
, Erik Lerkevang Grove
, Jøn Dalsgaard Nielsen
, Maja Hellfritzsch Poulsen

Afdeling for Blodsygdomme CKO

3 Citationer (Scopus)

Abstract

Managing anticoagulant therapy in patients with comorbidities such as kidney disease, liver disease, obesity, thrombophilia and increased bleeding risk with thrombocytopenia presents unique challenges. Renal impairment affects drug clearance. Liver disease alters coagulation and drug metabolism. Obesity affects drug distribution and dosing. Increased bleeding risk with thrombocytopenia often requires different dosing. This review finds that tailored therapeutic strategies are essential to balance the risks and benefits in these complex patient populations.

Bidragets oversatte titel	Anticoagulation therapy for complex patient populations
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	42
Sider (fra-til)	1-8
Antal sider	8
ISSN	0041-5782
DOI	https://doi.org/10.61409/V05240367
Status	Udgivet - 14 okt. 2024

Emneord

Humans
Anticoagulants/adverse effects
Obesity/complications
Hemorrhage/chemically induced
Thrombocytopenia/drug therapy
Liver Diseases/drug therapy
Thrombophilia/drug therapy
Kidney Diseases/complications
Risk Factors

Adgang til dokumentet

10.61409/V05240367Licens: CC BY-NC-ND

Citationsformater

@article{fc068e14ba1845b1932fecd9b6a77b1a,

title = "Antikoagulationsbehandling til s{\ae}rlige patientpopulationer",

abstract = "Managing anticoagulant therapy in patients with comorbidities such as kidney disease, liver disease, obesity, thrombophilia and increased bleeding risk with thrombocytopenia presents unique challenges. Renal impairment affects drug clearance. Liver disease alters coagulation and drug metabolism. Obesity affects drug distribution and dosing. Increased bleeding risk with thrombocytopenia often requires different dosing. This review finds that tailored therapeutic strategies are essential to balance the risks and benefits in these complex patient populations.",

keywords = "Humans, Anticoagulants/adverse effects, Obesity/complications, Hemorrhage/chemically induced, Thrombocytopenia/drug therapy, Liver Diseases/drug therapy, Thrombophilia/drug therapy, Kidney Diseases/complications, Risk Factors",

author = "Gro Egholm and Olesen, \{Jens Steen\} and Lein{\o}e, \{Eva Birgitte\} and Grove, \{Erik Lerkevang\} and Nielsen, \{J{\o}n Dalsgaard\} and Poulsen, \{Maja Hellfritzsch\}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = oct,

day = "14",

doi = "10.61409/V05240367",

language = "Dansk",

volume = "186",

pages = "1--8",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske L{\ae}geforening",

number = "42",

}

TY - JOUR

T1 - Antikoagulationsbehandling til særlige patientpopulationer

AU - Egholm, Gro

AU - Olesen, Jens Steen

AU - Leinøe, Eva Birgitte

AU - Grove, Erik Lerkevang

AU - Nielsen, Jøn Dalsgaard

AU - Poulsen, Maja Hellfritzsch

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/10/14

Y1 - 2024/10/14

N2 - Managing anticoagulant therapy in patients with comorbidities such as kidney disease, liver disease, obesity, thrombophilia and increased bleeding risk with thrombocytopenia presents unique challenges. Renal impairment affects drug clearance. Liver disease alters coagulation and drug metabolism. Obesity affects drug distribution and dosing. Increased bleeding risk with thrombocytopenia often requires different dosing. This review finds that tailored therapeutic strategies are essential to balance the risks and benefits in these complex patient populations.

AB - Managing anticoagulant therapy in patients with comorbidities such as kidney disease, liver disease, obesity, thrombophilia and increased bleeding risk with thrombocytopenia presents unique challenges. Renal impairment affects drug clearance. Liver disease alters coagulation and drug metabolism. Obesity affects drug distribution and dosing. Increased bleeding risk with thrombocytopenia often requires different dosing. This review finds that tailored therapeutic strategies are essential to balance the risks and benefits in these complex patient populations.

KW - Humans

KW - Anticoagulants/adverse effects

KW - Obesity/complications

KW - Hemorrhage/chemically induced

KW - Thrombocytopenia/drug therapy

KW - Liver Diseases/drug therapy

KW - Thrombophilia/drug therapy

KW - Kidney Diseases/complications

KW - Risk Factors

U2 - 10.61409/V05240367

DO - 10.61409/V05240367

M3 - Review

C2 - 39531027

SN - 0041-5782

VL - 186

SP - 1

EP - 8

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 42

ER -

Antikoagulationsbehandling til særlige patientpopulationer

Abstract

Emneord

Adgang til dokumentet

Fingeraftryk

Citationsformater